## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence presented in the abstract, as supplied
- **Shared manuscript claim summary** The authors report an in silico analysis of six missense PAX9 variants linked to severe oligodontia, using computational tools to predict deleterious effects, structural and functional alterations, and potential therapeutic target sites, with supporting evidence from gene ontology, protein interaction, PTM analysis, structural superimposition, conserved domain analysis, and MD simulations.
- **Visible evidence base** Abstract text only; no figures, tables, methods, or supplementary materials provided
- **Missing materials affecting confidence** Full manuscript, methods details, all figures and tables, supplementary data, statistical outputs, and simulation parameters

## Reviewer
- **Overall assessment** The abstract presents a potentially useful computational exploration of PAX9 variants associated with tooth agenesis, but the evidence base is insufficient to evaluate the validity of the claims. The study’s scope is narrow, and the abstract lacks quantitative results, methodological transparency, and clear links between computational predictions and biological relevance. The claim of "potential therapeutic targets" is not supported by the provided material, as no functional validation or mechanistic evidence is presented. The manuscript may be of interest to researchers in dental genetics and computational biology, but the current abstract does not establish the case for the stated conclusions.
- **Who would be interested in the results, and why** Researchers in dental genetics, particularly those studying tooth agenesis and PAX9-related disorders, may find the variant prioritization useful. Computational biologists and structural biologists interested in missense variant effects on protein structure and dynamics could also be interested. However, the lack of experimental validation limits broader appeal to clinical or translational audiences.
- **Major strengths** The study addresses a clinically relevant gene and focuses on variants with known disease association. The use of multiple computational algorithms and MD simulations suggests a systematic approach. The identification of KDM5B as a strong interacting partner may offer a novel hypothesis for future work.
- **Major Concerns**  
  - R1-M1  
  - R1-M2  
  - R1-M3  
  - R1-M4  
  - R1-M5
- **Minor Comments**  
  - R1-m1  
  - R1-m2  
  - R1-m3  
  - R1-m4
- **Technical failings that need to be addressed before the case is established** R1-M1, R1-M2, R1-M3, R1-M4, R1-M5
- **Assessment against Nature-style criteria**  
  - Originality: The approach is not novel, as similar in silico pipelines for missense variant analysis are common. The specific focus on PAX9 is a minor increment.  
  - Scientific importance: The topic is relevant to a rare condition, but the abstract does not demonstrate broad significance beyond a narrow genetic context.  
  - Interdisciplinary readership: The work may appeal to computational and dental genetics communities, but the abstract lacks clarity for nonspecialists in structural biology or clinical genetics.  
  - Technical soundness: Cannot be assessed from the abstract alone; no methodological details or quantitative results are provided.  
  - Readability for nonspecialists: The abstract is dense with jargon and lacks context for key terms such as "conserved domain analysis" and "MD simulations," reducing accessibility.
- **Recommendation posture** Currently not established from the provided evidence. The abstract does not provide sufficient data or methodological detail to support the core claims, particularly regarding therapeutic targets and functional consequences.

### Major Concerns

- **Concern ID** R1-M1  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Evidence sufficiency  
- **Claim pointer** The abstract claims that "structural and functional alterations" and "potential therapeutic target sites" are identified from the analysis.  
- **Evidence pointer** Abstract text, location not provided  
- **Concern** The abstract provides no quantitative data, such as scores from computational algorithms, RMSD values from structural superimposition, or simulation metrics from MD analyses. Without these, the claims of structural and functional alterations are unverifiable.  
- **Why it matters** The core conclusions depend on the reliability and magnitude of the predicted changes. The absence of numerical evidence prevents any assessment of effect size or statistical confidence.  
- **Resolution test** Provide specific values for each variant, including prediction scores, structural deviation measures, and MD simulation outputs, with appropriate statistical comparisons to wild-type.

- **Concern ID** R1-M2  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Methodological transparency  
- **Claim pointer** The abstract states that "several computational algorithm methods" and "MD simulations" were used.  
- **Evidence pointer** Abstract text, location not provided  
- **Concern** No details are given on which algorithms were used, their versions, thresholds for pathogenicity classification, or simulation parameters such as force fields, simulation length, or solvent conditions.  
- **Why it matters** Reproducibility is a fundamental requirement for computational studies. Without this information, the results cannot be independently verified or compared with existing literature.  
- **Resolution test** Include a methods section or supplementary material detailing all tools, parameters, and analysis pipelines.

- **Concern ID** R1-M3  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Claim support  
- **Claim pointer** The abstract claims that "unique sections that lacked DNA binding or protein-protein interaction sites" suggest "prospective drug target sites."  
- **Evidence pointer** Abstract text, location not provided  
- **Concern** The logic that absence of known functional sites implies druggability is not established. Drug targets require evidence of functional relevance, accessibility, and potential for modulation. No such evidence is presented.  
- **Why it matters** This is a strong translational claim that could mislead readers if unsupported. The abstract does not provide any docking, binding, or functional data to support therapeutic potential.  
- **Resolution test** Provide experimental or high-confidence computational evidence, such as druggability predictions, binding site analyses, or functional assays, to substantiate the claim.

- **Concern ID** R1-M4  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** External validation  
- **Claim pointer** The abstract states that "research on cell lines and animal models may be valuable in establishing their specific roles."  
- **Evidence pointer** Abstract text, location not provided  
- **Concern** This statement acknowledges the lack of experimental validation. The study is purely computational, and the abstract does not report any independent validation of the predictions.  
- **Why it matters** Computational predictions alone are insufficient to establish functional consequences, especially for a gene with known disease relevance. The absence of validation limits the confidence in all downstream claims.  
- **Resolution test** Include experimental validation, such as expression assays, functional studies, or animal models, or clearly state the study as hypothesis-generating without claims of established effects.

- **Concern ID** R1-M5  
- **Severity** Major  
- **Blocking** No  
- **Axis** Interpretive clarity  
- **Claim pointer** The abstract claims that "changes" from MD simulations "may all be impacted" on structure, compactness, stiffness, and function.  
- **Evidence pointer** Abstract text, location not provided  
- **Concern** The phrasing is vague and does not specify which variants show which effects. The use of "may" weakens the claim, but the abstract does not clarify the direction or magnitude of any predicted changes.  
- **Why it matters** Readers cannot determine whether the variants have distinct or shared effects, which is critical for understanding genotype-phenotype relationships.  
- **Resolution test** Provide a clear summary of per-variant effects on each property, with quantitative measures and comparisons to wild-type.

### Minor Comments

- **Concern ID** R1-m1  
- **Severity** Minor  
- **Axis** Terminology precision  
- **Affected element** "inclusive study" in the title  
- **Evidence pointer** Title, location not provided  
- **Issue** The term "inclusive" is ambiguous and does not convey a specific scientific meaning in this context.  
- **Required correction** Replace with a more descriptive term, such as "comprehensive" or "systematic," to accurately reflect the study scope.

- **Concern ID** R1-m2  
- **Severity** Minor  
- **Axis** Contextual framing  
- **Affected element** Introduction of PAX9 mutations  
- **Evidence pointer** Abstract text, location not provided  
- **Issue** The abstract states that the six variants are "linked to severe oligodontia" but does not specify the source of this linkage or the criteria for selection.  
- **Required correction** Briefly state the basis for variant selection, such as prior clinical reports or database entries, to provide context.

- **Concern ID** R1-m3  
- **Severity** Minor  
- **Axis** Clarity of interaction claim  
- **Affected element** "KDM5B as PAX9's strongest interacting partner similar to MSX1"  
- **Evidence pointer** Abstract text, location not provided  
- **Issue** The phrase "similar to MSX1" is unclear. It could mean KDM5B is a strong partner for both PAX9 and MSX1, or that the interaction strength is comparable to that of MSX1.  
- **Required correction** Clarify the intended comparison and provide interaction scores or confidence metrics.

- **Concern ID** R1-m4  
- **Severity** Minor  
- **Axis** Language precision  
- **Affected element** "structural changes in locations that were present in the structures of all six variations"  
- **Evidence pointer** Abstract text, location not provided  
- **Issue** The phrasing is awkward and ambiguous. It is unclear whether the same structural locations are altered in all variants or whether each variant has changes at distinct locations.  
- **Required correction** Rewrite to specify whether the changes are shared or variant-specific, with reference to specific structural regions.

## Risk / unsupported claims
- The claim of "potential therapeutic target sites" is unsupported, as no druggability or functional evidence is provided.
- The claim of "structural, functional alterations" is unverifiable without quantitative data.
- The statement that "research on cell lines and animal models may be valuable" is speculative and not part of the study results.
- The interaction with KDM5B is presented without supporting data or context, making it unassessable.
- All conclusions regarding MD simulation effects are unsubstantiated due to missing simulation details and outputs.